摘要:
Compounds of formula (I), N-oxides, pharmaceutical acceptable salts, quaternary amines or stereoisomeric forms thereof, and their use as HIV replication inhibitors, In the formula, -a1=a2-a3=a4- and -b1=b2-b3=b4- may be —C═C—C═C—; X1 may be O, NR1, etc.; R1, R2, R2a, R3, R4 and R5 are assorted substituents as defined in the specification.
摘要:
HIV replication inhibitors of formula wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and X have specific definitions, and pharmaceutical compositions containing these compounds as active ingredient and processes for preparing said compounds and compositions.
摘要:
The present invention provides compounds of formula (I) and compounds of formula (VII-a) as well as pharmaceutical compositions comprising said compounds and their use as PARP inhibitors wherein n, R1, R2, R3, R4, R5, R6, R7, Re, Rd and X have defined meanings.
摘要:
HIV replication inhibitors of formula R1 is hydrogen; aryl; formyl; C1-6alkylcarbonyl; C1-6alkyl; C1-6alkyloxycarbonyl; R2, R3, R6 and R7 are hydrogen; hydroxy; halo; C3-7cycloalkyl; C1-6alkyloxy; carboxyl; C1-6alkyloxycarbonyl; cyano; nitro; amino; mono- or di(C1-6alkyl)amino; polyhaloC1-6alkyl; polyhaloC1-6alkyloxy; —C(═O)R9; optionally substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl; R4 and R5 are hydroxy; halo; C3-7cycloalkyl; C1-6alkyloxy; carboxyl; C1-6alkyloxycarbonyl; formyl; cyano; nitro; amino; mono- or di(C1-6alkyl)amino; polyhaloC1-6alkyl; polyhaloC1-6alkyloxy; —C(═O)R9; cyano; —S(═O)rR9; —NH—S(═O)2R9; —NHC(═O)H; —C(═O)NHNH2; —NHC(═O)R9; Het; —Y-Het; optionally substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl; R5 is pyridyl, —C(═O)NR5aR5b; —CH(OR5c)R5d; —CH2—NR5eR5f; —CH═NOR5a; —CH2—O—C2-6alkenyl; —CH2—O—P(═O)(OR5g)2; —CH2—O—C(═O)—NH2; —C(═O)—R5d; X is —NR1—, —O—, —CH2—, —S—; pharmaceutical compositions containing these compounds as active ingredient and processes for preparing said compounds and compositions.
摘要翻译:式R1的HIV复制抑制剂是氢; 芳基; 甲酰基 C 1-6烷基羰基; C 1-6烷基; C 1-6烷氧基羰基; R2,R3,R6和R7是氢; 羟基; 光环; C 3-7环烷基; C 1-6烷氧基; 羧基; C 1-6烷氧基羰基; 氰基; 硝基 氨基; 单或二(C 1-6烷基)氨基; 多卤代C 1-6烷基; 多卤代C 1-6烷氧基; -C(-O)R 9; 任选取代的C 1-6烷基,C 2-6烯基或C 2-6炔基; R4和R5是羟基; 光环; C 3-7环烷基; C 1-6烷氧基; 羧基; C 1-6烷氧基羰基; 甲酰基 氰基; 硝基 氨基; 单或二(C 1-6烷基)氨基; 多卤代C 1-6烷基; 多卤代C 1-6烷氧基; -C(-O)R 9; 氰基; -S(-O)r R 9; -NH-S(-O)2 R 9; -NHC(-O)H; -C(-O)NHNH 2; -NHC(-O)R 9; Het; -Y-Het; 任选取代的C 1-6烷基,C 2-6烯基或C 2-6炔基; R5是吡啶基,-C(-O)NR5aR5b; -CH(OR 5 c)R 5d; -CH2-NR5eR5f; -CH-NOR5a; -CH 2 -O-C 2-6烯基; -CH 2 -O-P(-O)(OR 5 g)2; -CH 2 -O-C(-O)-NH 2; -C(-O)-R5d; X是-NR 1 - , - O - , - CH 2 - , - S- 含有这些化合物作为活性成分的药物组合物和制备所述化合物和组合物的方法。
摘要:
HIV replication inhibitors of formula wherein -a1=a2-a3=a4- is —CH═CH—CH═CH—, —N═CH—CH═CH—, —N═CH—N═CH—, —N═CH—CH═N—, —N═N—CH═CH—; -b1=b2-b3=b4- is —CH═CH—CH═CH—, —N═CH—CH═CH—, —N═CH—N═CH—, —N═CH—CH═N—, —N═N—CH═CH—; n and m is 0-4, R1 is hydrogen; aryl; formyl; C1-6alkylcarbonyl; C1-6alkyl; C1-6alkyloxycarbonyl; R2 is OH; halo; C1-6alkyl, C2-6alkenyl or C2-6alkynyl; substituted carbonyl; carboxyl; CN; nitro; amino; polyhalomethyl; polyhalomethylthio; —S(═O)pR6; C(═NH)R6; R2a is CN; amino; substituted amino; C1-6alkyl; halo; C1-6alkyloxy; carbonyl; —CH═N—NH—C(═O)—R16; C1-6alkyloxyC1-6alkyl; C2-6alkenyl or C2-6alkynyl; —C(═N—O—R8)—C1-4alkyl; R7 or —X—R7; R3 is CN; amino; C1-6alkyl; halo; C1-6alkyloxy; substituted carbonyl; —CH═N—NH—C(═O)—R16; substituted C1-6alkyl; C1-6alkyloxyC1-6alkyl; substituted C2-6alkenyl or C2-6alkynyl; —C(═N—O—R8)—C1-4alkyl; R7; —X—R7; R4 is halo; OH; C1-6alkyl, C2-6alkenyl or C2-6alkynyl; C3-7cycloalkyl; C1-6alkyloxy; CN; nitro; polyhaloC1-6alkyl; polyhaloC1-6alkyloxy; substituted carbonyl; formyl; amino; mono- or di(C1-4alkyl)amino or R7; -A-B— is —CR5═N—, —N═N—, —CH2—CH2—, —CS—NH—, —CO—NH—, —CH═CH—; and the use of these compounds for the prevention or the treatment of HIV infection.
摘要:
The present invention is related to novel compounds of formula (I) that inhibit the activity of the FabI enzyme which are therefore useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds.
摘要:
The present invention is related to novel compounds of formula (I) that inhibit the activity of the Fab1 enzyme which are therefore useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds.
摘要:
HIV replication inhibitors of formula R1 is hydrogen; aryl; formyl; C1-6alkylcarbonyl; C1-6alkyl; C1-6alkyloxycarbonyl; R2, R3, R6 and R7 are hydrogen; hydroxy; halo; C3-7cycloalkyl; C1-6alkyloxy; carboxyl; C1-6alkyloxycarbonyl; cyano; nitro; amino; mono- or di(C1-6alkyl)amino; polyhaloC1-6alkyl; polyhaloC1-6alkyloxy; —C(═O)R9; optionally substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl; R4 and R5 are hydroxy; halo; C3-7cycloalkyl; C1-6alkyloxy; carboxyl; C1-6alkyloxycarbonyl; formyl; cyano; nitro; amino; mono- or di(C1-6alkyl)amino; polyhaloC1-6alkyl; polyhaloC1-6alkyloxy; —C(═O)R9; cyano; —S(═O)rR9; —NH—S(═O)2R9; —NHC(═O)H; —C(═O)NHNH2; —NHC(═O)R9; Het; —Y-Het; optionally substituted C1-6alkyl, C2-6alkenyl or C2-6alkynyl; R5 is pyridyl, —C(═O)NR5aR5b; —CH(OR5c)R5d; —CH2—NR5eR5f; —CH═NOR5a; —CH2—O—C2-6alkenyl; —CH2—O—P(═O)(OR5g)2; —CH2—O—C(═O)—NH2; —C(═O)—R5d; X is —NR1—, —O—, —CH2—, —S—; pharmaceutical compositions containing these compounds as active ingredient and processes for preparing said compounds and compositions.
摘要:
HIV replication inhibitors of formula a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof, wherein A is —CH2—CH2—, —CH═CH—, —C≡C—; R1 is hydrogen, aryl, formyl, C1-6alkylcarbonyl, C1-6alkyl, C1-6alkyloxycarbonyl, R2 hydroxy, halo, C1-6alkyl, carboxyl, cyano, —C(═O)R6, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl; X1 is —NR1—, —O—, —S—, —S(═O)p—; R3 is H, C1-6alkyl, halo; R4 is H, C1-6alkyl, halo; R5 is nitro, amino, mono- and diC1-4alkylamino, aryl, halo, —CHO, —CO—R6, —COOR7, —NH—C(═O)H, —NH—C(═O)R6, —CH═N—O—R8; R6 is C1-4alkyl, amino, mono- or di(C1-4alkyl)amino or polyhaloC1-4alkyl; R7 is hydrogen, C1-6alkyl, arylC1-6alkyl; R8 is hydrogen, C1-6alkyl, aryl; p is 1 or 2; aryl is optionally substituted phenyl; pharmaceutical compositions containing these compounds as active ingredient and processes for preparing said compounds and compositions.
摘要翻译:其中A是-CH 2 -CH 2 - , - CH = CH - , - C≡C-;其中A是-CH 2 -CH 2 - , - CH = CH - , - C≡C-; R1是氢,芳基,甲酰基,C1-6烷基羰基,C1-6烷基,C1-6烷氧基羰基,R2羟基,卤素,C1-6烷基,羧基,氰基,-C(= O)R6,硝基,氨基,单或二 C 1-6烷基)氨基,多卤甲基; X 1是-NR 1 - , - O - , - S - , - S(= O)p - ; R 3是H,C 1-6烷基,卤素; R4是H,C1-6烷基,卤素; R 5是硝基,氨基,单和二C 1-4烷基氨基,芳基,卤素,-CHO,-CO-R 6,-COOR 7,-NH-C(= O)H,-NH-C(= = N-O-R8; R 6是C 1-4烷基,氨基,单或二(C 1-4烷基)氨基或多卤代C 1-4烷基; R 7是氢,C 1-6烷基,芳基C 1-6烷基; R8是氢,C1-6烷基,芳基; p为1或2; 芳基是任选取代的苯基; 含有这些化合物作为活性成分的药物组合物及其制备方法。
摘要:
This invention concerns pyrimidine derivatives of formula having HIV (Human Immunodeficiency Virus) replication inhibiting properties, the preparation thereof and pharmaceutical compositions comprising these compounds.